Natural Alternatives (NAII) Trades Down Over 12% on Q4 Earnings Report
The supplement and health centric company Natural Alternatives (NAII) is lagging the PRISM Consumer Products Index today upon the announcement of its Q4 earnings that was released after the close on Friday.
The company reported a net loss of $1.9M million, or ($0.32) per diluted share, on net sales of $29.5M for Q4 compared to a net income of $2.0M, or $0.35 per diluted share, in Q4 of the prior fiscal year.
Net sales during the three months ended June 30, 2024, decreased $6.4M to $29.5M as compared to $35.9M recorded in the comparable prior year period. Reduced orders from one of Natural Alternatives largest customers contributed mainly to a reduction in private-label manufacturing sales. Additionally CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 48% to $1.85M in Q4 as compared to $3.57M million for Q4 of 2023. The decrease was primarily due to decreased raw material sales and unfavorable changes in estimates for volume rebates.
As of June 30, 2024, the company has a cash position of $12M and working capital of $38.1M, compared to $13.6M in cash and $41.M of working capital, as of June 30, 2023
Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “As planned, our Carlsbad powder facility re-opened in the fourth quarter with on-going production to meet our customer requirements. We continue to gain traction with new business opportunities and expect these efforts to bear fruit in the coming months. Our new business opportunity pipeline remains healthy, and we are optimistic these opportunities will generate positive sales growth and pave our pathway back to profitability.”
